home / stock / syn / syn news

SYN News and Press, Synthetic Biologics Inc. From 06/30/20

Stock Information
Company Name: Synthetic Biologics Inc.
Stock Symbol: SYN
Market: NYSE
Website: syntheticbiologics.com
Menu
SYN SYN Quote SYN Short SYN News SYN Articles SYN Message Board
Get SYN Alerts

News, Short Squeeze, Breakout and More Instantly...
SYN - Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase

ROCKVILLE, Md. , June 30, 2020 /PRNewswire/ --  Synthetic Biologics, Inc.  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need...
SYN - Synthetic Bio inks deal to advance development of candidate SYN-020

Synthetic Biologics (NYSEMKT: SYN ) has entered into an agreement with Massachusetts General Hospital (MGH), granting the company an option for an exclusive license to intellectual property and technology for the use of intestinal alkaline phosphatase to maintain GI and microbiome health, ...

SYN - Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases

ROCKVILLE, Md. , May 27, 2020 /PRNewswire/ --  Synthetic Biologics, Inc.  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need,...

SYN - Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET Company Participants Vincent Perrone – Director-Corporate Communication Steven Shallcross – Chief Executive and Financial Officer Vince Wacher – Head-Product and Corporate...
SYN - Synthetic Biologics EPS beats by $0.07

Synthetic Biologics (NYSEMKT: SYN ): Q1 GAAP EPS of -$0.20 beats by $0.07 . More news on: Synthetic Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SYN - Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results

ROCKVILLE, Md. , May 5, 2020 /PRNewswire/ --  Synthetic Biologics, Inc.  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need,&#x...

SYN - Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020

ROCKVILLE, Md. , April 28, 2020 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced...
SYN - Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) Q4 2019 Earnings Conference Call February 20, 2020 4:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - Chief Executive Officer and Chief Financial Officer Vince Wacher - Head of Product and Corpo...

SYN - Synthetic Biologics EPS beats by $0.05

Synthetic Biologics (NYSEMKT: SYN ): FY GAAP EPS of -$0.98 beats by $0.05 . Cash and cash equivalents of $15.05M Press Release More news on: Synthetic Biologics, Inc., Earnings news and commentary, Healthcare stocks news, ,

SYN - Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results

ROCKVILLE, Md. , Feb. 20, 2020 /PRNewswire/ -- Synthetic Biologics, Inc.  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, ...
Previous 10 Next 10